

Algal Bio Acquire EBIS Algae Research Institute To Integrate EPA-rich Nannochloropsis Business

*Aiming to be the top in the Global Market with an EPA-rich Nannochloropsis
Through Achieving Sustainable Aquaculture and Well-Being*


TOKYO, Japan, March 19, 2025 - Algal Bio, a company specializing in the development of innovative products and solutions derived from microalgae, has acquired the management rights of EBIS Algae Research Institute. This acquisition is in line with Algal Bio's mission to "Cultivating Algae's Potential for a Better Future", underscoring its commitment to driving advancements in the field.



EBIS Algae Research Institute is a Japan-based company with a rare raceway-based commercial production facility for the development, production and marketing of Nannochloropsis (*), a microalgae containing the highly unsaturated fatty acid EPA (eicosapentaenoic acid), which is essential for sustainable aquaculture and health.

Through this acquisition of management rights, we will develop an integrated microalgae business from R&D to commercial production of a wide variety of microalgae by combining our microalgae bio-foundry platform with EBIS's business infrastructure. In addition to Nannochloropsis for marine feed, which EBIS already produces and sells, we will accelerate the development of new microalgae species for marine feed. Our goal is to become the leading global microalgae company for marine feed.

About Nannochloropsis: <https://www.ebisalgae.com/en/>



EBIS's Microalgae Raceway ponds located in Ishinomaki, Miyagi, Japan
And Nannochloropsis

Since its establishment in 2018, Algal Bio has built a unique microalgae bio-foundry platform with an extensive microalgae library of over 1260 strains of 100 species. Leveraging this platform, we have developed a market-in business model that encompasses the selection and breeding of microalgae species for specific applications, the development of cultivation and production technologies, and the search for optimal production culture conditions. In September 2023, we opened the Yokohama Manufacturing Technology Center, which houses a photobioreactor with a maximum capacity of 5 tons. We have established a consistent system for researching and developing scale-up culture technology.


This business integration will combine EBIS's seawater-based raceway commercial production facilities with our microalgae bio-foundry platform to establish a strong technological foundation from basic research to commercialization of microalgae. In addition, it will establish a R&D platform that can meet diverse business needs.

In FY2024, both companies have over 40 joint development projects in operation with client companies that are focused on developing new microalgae products and solutions. The integration will also help accelerate the commercialization of each project.

In addition, EBIS is well-known for its high domestic market share in producing and marketing EPA-rich microalgae feed for fry and juvenile fish. By leveraging the advanced breeding, cultivation, and application development technologies developed at our cutting-edge microalgae bio-foundry platform to EBIS, we aim to become the global market leader in the algae business for marine feed. This will be achieved by developing new products at EBIS using new algae species selected from our microalgae library.



Expansion of microalgae bio-foundry platform



Further updates to the microalgae bio-foundry platform
Realization of consistent promotion of basic research to commercial production

About EBIS Algae Research Institute

Established in 2018. Has a raceway-style commercial production facility in Ishinomaki City, Miyagi Prefecture. EBIS is a specialist in the manufacturing of Nannochloropsis, a marine microalgae that is known for its high EPA content, and its marine feed products account for over 25% of the domestic market.

About Algal Bio

Algal Bio is a R&D-oriented startup company, dedicating to unleashing the potential of microalgae with the mission of “Cultivating Algae's Potential for a Better Future”. We are building the most advanced microalgae bio-foundry platform in the world. Our platform is based on the results of more than 20 years of microalgae research at the University of Tokyo. It consists of a proprietary microalgae library that accumulates culture data on 1,260 strains of 100 species, as well as breeding and selection technologies for each microalgae, know-how for optimizing culture conditions, and a pilot plant for scale-up studies. Our platform will provide the clients with the best possible microalgae for their needs in the shortest possible time. By leveraging our algae bio-foundry platform, we collaborate with a diverse range of companies to bring new algae-derived products and solutions to market. These innovations address critical global challenges, including human health, sustainable food supply, and climate change.

For more info: <https://algalbio.co.jp/en/>

<Contact>

Algal Bio Co., Ltd.

Tel : +81- 4-7138-6207

E-mail : info@algalbio.co.jp

URL : <https://algalbio.co.jp/en/>